Shenzhen Geno-immune Medical Institute

This Phase 1 trial tests a new type of COVID-19 vaccine made from artificial antigen presenting cells (aAPC). The vaccine is designed to teach the body's T cells to recognize and attack the SARS-CoV-2 virus. The study includes healthy volunteers and people with mild COVID-19, and…

This trial tests a new vaccine called LV-SMENP, designed to teach the body's immune cells to recognize and attack the COVID-19 virus. The vaccine uses a harmless virus to deliver pieces of the coronavirus into dendritic cells, which then activate T cells to fight infection. The s…

This study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…

This study tests a gene therapy given by IV for ADA-SCID, a rare and life-threatening immune disorder. The treatment uses a modified virus to deliver a working gene, aiming to restore the immune system. Ten participants will be monitored for safety and immune recovery over one ye…

This early-stage trial tests a new type of immunotherapy called 4SCAR-T cells in 20 people with advanced bladder cancer that has spread and no longer responds to standard treatments. The cells are genetically modified to recognize and attack cancer cells. The study aims to see if…

This early-stage trial tests a personalized dendritic cell vaccine in 10 multiple myeloma patients who are already in very good remission. The vaccine is designed to train the immune system to keep the cancer from returning. The main goal is to see if the vaccine is safe, with a …

This trial tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD70, found on certain B cell cancers. The treatment involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing …

This early-stage trial tests a gene therapy for people with hemophilia A, a bleeding disorder. The treatment uses a modified virus to deliver a working gene into the patient's own stem cells, which are then infused back. The goal is to help the body produce clotting factor VIII, …

This trial tests a gene therapy for Fanconi anemia, a rare genetic disorder that causes bone marrow failure and increases cancer risk. Participants receive their own stem cells that have been genetically corrected with a lentiviral vector to fix the faulty FANCA gene. The study e…

This study tests a new type of immunotherapy called CAR T cells that are designed to recognize several different targets on multiple myeloma cancer cells. The treatment involves taking a patient's own immune cells, modifying them in a lab to better attack the cancer, and infusing…

This study tests a new type of cell therapy called GD2/CD70 bi-specific CAR-T cells for people with cancers that have GD2 or CD70 markers on their tumors. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack these markers, and infusin…

This early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…

This study tests a new treatment for people with advanced or recurrent cervical cancer linked to high-risk HPV. The treatment uses specially engineered immune cells (CC-EIEs) designed to target and attack the cancer. Participants receive several infusions of these cells, and rese…

This early-stage trial is testing whether specially engineered immune cells (called CAR-T and CTL cells) and a dendritic cell vaccine can safely treat people with neurofibromatosis or schwannomatosis, conditions that cause nerve tumors. The study will enroll 100 participants aged…

This study tests a new approach using a mix of gene-modified immune cells (CAR-T cells) that target multiple proteins found on B cell lymphoma cells. The goal is to see if this combination is safe and can shrink tumors in patients whose cancer has not responded to standard treatm…

This early-phase trial tests a new type of cell therapy for people with relapsed or refractory acute myeloid leukemia (AML). The treatment uses a patient's own immune cells, engineered to recognize six different targets on leukemia cells. The study aims to see if this approach is…

This study tests a new type of CAR T-cell therapy for people with B-cell leukemia that does not have the CD19 protein, often because it stopped responding to earlier CAR T treatment. The modified immune cells target six different markers on leukemia cells. The trial aims to see i…

This early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…

This study tests a new treatment called 4SCAR19 cells for people with B-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The trial aims to check safety…

This study tests a new treatment called bi-specific CAR-T cells that target two proteins, PSMA and CD70, found on some cancer cells. The therapy involves taking a patient's own immune cells, engineering them to recognize and attack these proteins, and infusing them back. The tria…

This early-phase trial tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if it is safe and can control the disease as a first treatment. About 20 participants will…

This trial tests a gene therapy given by IV for X-linked severe combined immunodeficiency (SCID-X1), a rare immune disorder. Ten participants with no matched donor will receive a lentiviral vector to correct the genetic defect. The goal is to restore immune function and improve s…

This trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims …

This trial investigates a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia (B-ALL) whose cancer has stopped responding to anti-CD19 treatment. The therapy uses a patient's own immune cells, modified to target several other markers on leukemia cel…

This study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD22, on the surface of B cell cancer cells. The treatment involves infusing these engineered immune cells into patients whose B cell malignancies have returned or not r…

This study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD79b, found on B cell cancers. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back…

This study tests a new treatment using a patient's own immune cells, engineered to recognize and attack cancer cells that have two specific markers (GD2 and CD56). The trial includes 60 people with advanced cancers that have not responded to standard therapy. The goal is to see i…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This early-stage trial is testing a new type of cell therapy called universal CAR-T cells for people with multiple myeloma that has not been cured by standard treatments. The therapy uses donor cells modified to target myeloma cells, aiming to be a ready-made option. The study wi…

This trial tests whether infusing HPV-specific immune cells (HPV-CTLs) can safely reduce or clear HPV infection in people who haven't responded to standard treatments. Up to 100 participants will receive 2 to 4 infusions of these cells. The study measures safety and viral load ch…

This study tests a new treatment using specially engineered immune cells (4SCAR-T cells) that target three different markers on breast cancer cells: GD2, Her2, and CD44v6. The goal is to see if this approach is safe and can shrink tumors in people with advanced or relapsed breast…

This study is testing a new treatment called 4SCAR-PSMA T cells for people whose cancers have a specific marker called PSMA. The therapy involves collecting a patient's own immune cells, modifying them to better recognize and attack cancer cells, and infusing them back. Up to 100…

This early-phase trial is testing whether specially engineered immune cells (OC-CTLs) can safely fight ovarian cancer. Twenty women with advanced-stage disease will receive 2 to 4 infusions of these cells. Researchers will monitor side effects and check if tumors shrink or stabil…

This trial tests a combination of genetically modified immune cells (CAR-T cells) that target CD19 plus another protein on B-cell cancers. The goal is to improve treatment for patients whose cancer has returned or not responded to standard therapy. The study enrolls 100 participa…

This early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…

This early-stage trial is testing a combination of specially engineered immune cells (CAR T cells) and a vaccine for people with sarcoma that has come back or spread. The goal is to see if the treatment is safe and can help shrink tumors. About 20 participants will receive the th…

This study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and…

This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This early-phase trial tests a two-part immune therapy for people with T-cell acute lymphoblastic leukemia (T-ALL). First, patients receive specially engineered T cells (CAR-T) that target multiple markers on leukemia cells. Then, they get a booster with cytotoxic T cells and a d…

This trial tests a gene therapy for metachromatic leukodystrophy (MLD), a rare and life-threatening genetic disorder that damages the nervous system. The treatment uses a lentivirus to deliver a working copy of the ARSA gene directly into the spinal fluid and bloodstream. Up to 1…

This trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…

This early-phase trial tests a combination of CAR T cells that target three different markers (CLL-1, CD33, and CD123) on leukemia cells in patients with relapsed or refractory acute myeloid leukemia. The study aims to see if this approach is safe and can shrink tumors. Only 10 p…

This phase 1 trial tests a new type of immunotherapy called universal CAR T cells in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The cells are engineered to recognize and attack leukemia cells by targeting four different proteins (CL…

This early-phase trial tests a new 'universal' CAR T cell therapy (4SCAR19U) for people with B cell cancers that have come back or not responded to treatment. The therapy uses donor-derived immune cells engineered to target CD19 on cancer cells. The study aims to check safety and…

This trial tests a 4th-generation safety-engineered CAR T cell therapy for people with relapsed or late-stage sarcomas, including osteosarcoma and Ewing sarcoma. Participants receive a single infusion of these immune cells designed to target and attack sarcoma cells. The study ai…

This trial investigates whether specially grown immune cells, called pathogen-specific cytotoxic T lymphocytes (CTLs), can safely and effectively treat stubborn infections like EBV, CMV, and adenovirus in people with weakened immune systems, such as stem cell or organ transplant …

This study tests a new treatment for gastrointestinal cancer using a patient's own immune cells, which are engineered in a lab to target cancer. About 100 participants will receive these cells to see if they are safe and can shrink tumors. The trial is currently recruiting and co…

This clinical trial tests a new type of immunotherapy called 4SCAR-T, which uses a patient's own immune cells engineered to recognize and attack three different markers (GD2, PSMA, and CD276) on neuroblastoma cancer cells. The study enrolls children and adults (ages 1 to 65) with…

This trial tests a gene therapy for chronic granulomatous disease (CGD), a rare immune disorder that leaves patients vulnerable to severe infections. Ten patients will receive their own stem cells modified with a lentivirus to correct the faulty gene. The goal is to restore immun…

This study tests whether specially engineered immune cells (EIE) can safely fight cancer. Researchers take a patient's own immune cells, modify them to target tumor-related markers, and infuse them back. The trial involves 100 people with various cancers whose tumors show specifi…

This Phase 1 trial tests a gene therapy that uses a lentivirus to deliver a working clotting factor IX gene into patients' own stem cells. Ten males with severe hemophilia B will receive the modified cells. The goal is to see if it's safe and can raise clotting factor levels, pot…

This study tests a new therapy using a patient's own immune cells, engineered to target a specific mutation found in diffuse midline glioma and DIPG, aggressive brain tumors. About 30 participants with recurrent or refractory disease will receive one to two infusions of these cel…

This study tests a new treatment using clonal fetal mesenchymal stem cells (cfMSCs) for people with type 2 diabetes. The goal is to see if it is safe and can improve blood sugar control. Thirty adults with poorly controlled diabetes will receive the stem cell therapy and be monit…

This early-stage trial is testing whether infusions of clonal fetal mesenchymal stem cells (cfMSCs) are safe and can help control severe symptoms in people with moderate to severe COPD. About 30 adults aged 40-80 who have not responded well to standard treatments will receive the…

This study tests a new treatment for people with advanced melanoma that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, NG2 and DLL3, found on melanoma cells. The goal is to see if th…

This study tests a new treatment called 4sCAR-DLL3 CAR-T cells for people with DLL3-positive brain tumors, including glioblastoma and certain midline gliomas. The therapy uses a patient's own immune cells, modified to target and attack tumor cells. The trial will enroll 30 partic…

This early-phase trial tests a combination of three immune cell therapies—CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell vaccines—against advanced melanoma that has not responded to standard treatment. The study aims to see if this approach is safe and can shrink…

This trial tests a new treatment for advanced ovarian cancer using a patient's own immune cells, called T cells, that are modified in a lab to better recognize and attack the cancer. About 100 women with stage III or IV ovarian cancer will receive these modified cells. The main g…

This trial tests a gene therapy for X-linked adrenoleukodystrophy (X-ALD), a rare genetic disease that damages the brain. The therapy uses a modified virus to deliver a working copy of the faulty gene directly into the spinal fluid and bloodstream. Up to 30 patients aged 1 year a…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…